Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
Principal Investigator
Alla Sikorskii, PhD,
Status
Open to Accrual
Date Opened To Accrual
May 20 2024
Disease Site
Cancer Care Delivery Research [CD]
Other
Phase
Other
Developmental Therapeutics
No
Primary Objective
Test the effectiveness of Automated Telephone System Management (ATSM) + Telephone Interpersonal Counseling (TIPC) versus active control on patient-level outcome of the summary toxicity index of 24 PRO-CTCAE symptoms that include depressive, anxiety, and other symptoms commonly experienced during oral anti-cancer treatment over weeks 1-12 (immediate effect) and 13-17 (sustained effect).
Patient Population
Participants who have started an oral anti-cancer treatment other than hormonal therapy within the past 4 weeks.
Additional Information About NRG-CC012CD
This study is also looking to enroll practices and personnel.
Practice Eligibility: Practices (defined as a single NCORP affiliate or sub-affiliate; or NCORP affiliate and/or sub-affiliates that share the same physicians and/or staff but are in different locations) will be randomized to the adaptive ATSM+TIPC intervention or active control once all eligibility criteria specified below have been met. After approval of the letter of intent to participate in NRG-CC012CD a practice will have 90 days to complete protocol training.
Recruitment:
Practice personnel = 48
Number of Practices = 12
Target Accrual
516